title: Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.
abstract: OBJECTIVE
  To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women.
  
  
  METHODS
  Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period. There was no lifestyle intervention. The primary outcome was change in body weight.
  
  
  RESULTS
  Subjects treated with exenatide lost an average of 2.49 ± 0.66 kg compared with a 0.43 ± 0.63 kg weight gain during placebo treatment. Weight loss with exenatide treatment was noted at 2 weeks. The degree of weight loss could be stratified. A total of 30% of subjects were high responders who lost ≥5% body weight (-7.96 ± 0.52%), 39% were moderate responders who lost <5% body weight (-2.43 ± 0.45%), and 31% were nonresponders who gained weight (1.93 ± 0.53%). Waist circumference also decreased significantly with exenatide treatment. Subjects experienced more nausea during exenatide treatment compared with placebo, but the severity decreased over time and did not correlate with weight loss.
  
  
  CONCLUSIONS
  Short-term exenatide treatment was associated with modest weight loss and decreased waist circumference in a cohort of obese nondiabetic women. A subset of individuals demonstrated robust weight loss that was detected very early in the course of treatment.
authors: Department of Medicine, Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.jdushay@bidmc.harvard.edu
authors: Jody
authors: J
authors: Dushay
authors: Chuanyun
authors: C
authors: Gao
authors: Gosala S
authors: GS
authors: Gopalakrishnan
authors: Meghan
authors: M
authors: Crawley
authors: Emilie K
authors: EK
authors: Mitten
authors: Elissa
authors: E
authors: Wilker
authors: Janet
authors: J
authors: Mullington
authors: Eleftheria
authors: E
authors: Maratos-Flier
mesh_terms: D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D000077270:Exenatide; D005260:Female; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009765:Obesity / Q000188:drug therapy*; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D018027:Receptors, Glucagon / Q000819:agonists; D014688:Venoms / Q000009:adverse effects / Q000627:therapeutic use*; D055105:Waist Circumference / Q000187:drug effects; D015431:Weight Loss / Q000187:drug effects
chemical_list: C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D010455:Peptides; D018027:Receptors, Glucagon; D014688:Venoms; D000077270:Exenatide